Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs
Open Access
- 6 February 2014
- journal article
- research article
- Published by Wiley in ISRN Dermatology
- Vol. 2014, 1-8
Abstract
Background. We wanted to verify retrospectively the proportion of patients with psoriatic arthritis who were in remission after 1 year of continuous therapy with either etanercept or adalimumab. Remission was defined as the absence of both clinical and contrast-enhanced ultrasound (CEUS) findings suggestive of joint inflammation. Patients and Methods. The data of twenty-five patients with psoriatic arthritis were available for the clinical and CEUS evaluations before and after 1 year of continuous therapy with etanercept or adalimumab. The count of swollen (ACR66), tender (ACR68), and active inflamed joints (AJC) was used to measure the severity of joint involvement. PASI was used to score the severity of psoriasis. HAQ, DLQI, VAS pain, and VAS itching were administered to each patient before starting therapy and every 3 months, up to 1 year. Results. Eight (32%) out of twenty-five patients were in remission after 1 year of therapy with etanercept or adalimumab. A significant reduction of all clinical variables analysed was seen during the course of therapy. Conclusion. Although a significant proportion of patients achieved remission of arthritis after 1 year of effective anti-TNF therapy, the majority of them continued to have either clinical or CEUS findings suggestive of persistence of joint inflammation.Keywords
This publication has 27 references indexed in Scilit:
- The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasisJournal of the European Academy of Dermatology and Venereology, 2011
- Recognizing psoriatic arthritis in the dermatology clinicJournal of the American Academy of Dermatology, 2010
- Comparative Effectiveness Without Head-to-Head TrialsPharmacoEconomics, 2010
- Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugsClinical Rheumatology, 2010
- The diagnosis and treatment of early psoriatic arthritisNature Reviews Rheumatology, 2009
- Criteria, Frequency, and Duration of Clinical Remission in Psoriatic Arthritis Patients with Peripheral Involvement Requiring Second-line DrugsThe Journal of Rheumatology, 2009
- A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experienceRheumatology, 2003
- Remission in psoriatic arthritis.2001
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- RELIABILITY OF MEASUREMENTS OF ACTIVE AND DAMAGED JOINTS IN PSORIATIC-ARTHRITIS1990